At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 426 enrolled
Drug / intervention
Troriluzole +1 moredrug
Likely dose
Troriluzole 140 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder
In Brief
A Phase 3 clinical trial evaluating Troriluzole and Placebo for Obsessive-Compulsive Disorder. Completed, enrolled 426 participants across 57 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy of troriluzole as adjunctive therapy versus placebo in participants with obsessive compulsive disorder (OCD) who had an inadequate response to selective serotonin reuptake inhibitor (SSRI), clomipramine, venlafaxine, or desvenlafaxine treatment
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObsessive-Compulsive Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedOct 2017
Enrollment StartDec 2017
Primary CompletionJun 2020
Study CompletionDec 2025
TodayJul 2026
First PostedOct 2, 2017
Enrollment StartDec 19, 2017
Primary CompletionJun 2, 2020
Study CompletionDec 8, 2025
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 8.8 years ago
Interventions
Troriluzoledrug
Troriluzole, 140 mg capsules once daily (QD) orally for the first 4 weeks and 200 mg (140 mg+ 60 mg capsules QD) for an additional 8 weeks
Placebodrug
Matching capsule once daily (QD)